The starting dosage of CD3+CD56- CAR T cells in this trial was comparable to those used in conventional CAR T-cell studies (2–7.5 × 106 cells/kg), as the CD3+CD56- subset accounted for nearly half of CAR CIK cells (up to 15 × 106 bulk cells/kg) (7), further suggesting that CAR T cells cultured under this condition were well tolerated with low risk of GVHD occurrence. This evidence concerns the gene NCAM1 and graft versus host disease.